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Background: Recent controversy surrounding interaction between proton pump inhibitors and clopidogrel has lead to an FDA warning advising 
against the simultaneous use of these medications. This warning stems from studies indicating reduced antiplatelet activity in some patients taking 
clopidogrel. However, the clinical impact of this interaction is unclear with regards to adverse cardiac outcomes, and reduction in bleeding events. To 
investigate this, we performed a Bayesian meta-analysis of adverse outcomes in patients taking PPIs and clopidogrel, and conducted a net-clinical 
benefit analysis. 
Methods: A literature search identified 6 RCTs or matched trials involving patients randomized to aspirin and clopidogrel, plus PPI or placebo. 
Major endpoints evaluated were MI/ACS, overall mortality, and major adverse cardiovascular events. Seven trials were found that contained either 
randomized or retrospective data regarding the major GI adverse outcomes of patients on aspirin and clopidogrel, randomized to PPI or placebo 
groups. A Bayesian meta-analysis was performed on each group, defining probabilities of benefit for the posterior probability. From this data, net 
clinical benefit calculations were performed and posterior probabilities were obtained. 
Results: Posterior probabilities for ACS/MI, mortality, and MACE did not indicate significant impact of PPI use on these endpoints, with posterior 
probabilities of benefit of 45%, 66%, and 53% respectively. Further, adverse GI outcomes were substantially reduced in patients taking PPIs, with 
a 99% probability of benefit, and a 77% probability of at least a 30% benefit. The net clinical probability of benefit is significant, with a 93% 
probability of benefit, and a 65% probability of at least a 30% benefit. 
Conclusions: Despite recent studies prompting an FDA warning regarding an interaction between clopidogrel and proton-pump inhibitors, Bayesian 
meta-analysis suggests little to no clinical impact of this interaction on major adverse cardiovascular events. Further, there appears to be a strong, 
beneficial impact of using PPIs with dual-antiplatelet therapy, with significant reductions in adverse GI complications.
